US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist
  • 0.726
  • +0.029+4.13%
Close Oct 31 16:00 ET
  • 0.740
  • +0.014+1.97%
Post 20:01 ET
185.57MMarket Cap-2015P/E (TTM)

Adaptimmune Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Adaptimmune Therapeutics Q3 2024 Estimates Date

Currency：USDNov 13, 2024

Estimate YoY
Revenue
20.49M
+179.94%
EPS
-0.08
-160.54%
Analyst Rating
Buy

Oct 31, 2024

Adaptimmune Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 9 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 12.155M--
Nov 13, 20242024/Q3-- / 20.489M--
Aug 12, 20242024/Q2128.231M / 44.762M--
May 15, 20242024/Q15.678M / 20.480M--
Mar 6, 20242023/Q4231.000K / 25.960M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 12.155M--
Nov 13, 20242024/Q3-- / 20.489M--
Aug 12, 20242024/Q2128.231M / 44.762M--
May 15, 20242024/Q15.678M / 20.480M--
Mar 6, 20242023/Q4231.000K / 25.960M--

Unlock Free Earnings Estimates

Adaptimmune Therapeutics Earnings Reports

  • Adaptimmune Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 12 07:26 ET

  • Adaptimmune Therapeutics | 10-Q: Q1 2024 Earnings Report

    May 15 22:23 ET

  • Adaptimmune Therapeutics | 10-K: FY2023 Annual Report

    Mar 6 07:18 ET

  • Adaptimmune Therapeutics | 10-Q: Q3 2023 Earnings Report

    Nov 8, 2023 16:05 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Oct 31, 2024

    Buy

    • Buy

      62.50%

    • Hold

      25.00%

    • Sell

      12.50%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data

    Concept CAR-T Therapy
    CAR-T Therapy
    Intraday-0.31%